Ark Clinical Research Leading the Way in Non-Opioid Pain?Research The FDA’s approval of Journavx (suzetrigine), the first non-opioid pain reliever in over two decades, marks a breakthrough in pain management. Ark Clinical Research is at the forefront of this advancement, conducting studies on this new class of pain treatments to expand safe and effective alternatives to opioids. Led by Dr. Justin Yanuck, a dual-certified Pain and Emergency Medicine specialist, Ark is leveraging its expertise, strong infrastructure, and diverse patient access to drive innovation in pain research. With?our?mobile unit reaching underserved populations, Ark is committed to ensuring equitable access to groundbreaking treatments. https://lnkd.in/gCMiGfZ9
关于我们
Ark Clinical Research pioneers transformative clinical trials across diverse medical domains, including Infectious Disease/Vaccines, Metabolic Disease, Liver Disease, Cardiovascular Disease, Allergy/Asthma, and CNS (Neurology/Psychiatry/General Medicine). Specializing in all phases of clinical trials, our commitment to advancing medical knowledge and innovation is evident in our collaborative approach with leading experts. By employing state-of-the-art research methodologies, Ark Clinical Research plays a crucial role in developing cutting-edge therapies for infectious diseases, metabolic disorders, liver conditions, cardiovascular issues, asthma, allergic reactions, and central nervous system disorders. Through our dedication, we aim to translate research findings into impactful solutions, enhancing patient care and well-being.
- 网站
-
www.arkclinicalresearch.com
Ark Clinical Research的外部链接
- 所属行业
- 研究服务
- 规模
- 51-200 人
- 总部
- Long Beach,California
- 类型
- 私人持股
- 创立
- 2016
- 领域
- clinical research、outpatient clinical trials、respiratory clinical research、internal medicine、dermatology clinical research、outpatient clinical trials、late phase clinical trials、phase 2 clinical research、phase 3 clinical reseach和covid vaccine
地点
Ark Clinical Research员工
动态
-
Let’s raise awareness about kidney health and the importance of early detection and prevention. At ARK, we are committed to advancing research and improving lives through clinical studies! #BetterResearchforaBetterLife
-
-
Today is National Women and Girls HIV/AIDS Awareness Day! Let’s raise awareness, support those affected, and work toward a healthier future for all. At ARK, we are committed to advancing research and making a difference. #BetterResearchforaBetterLife
-
-
Happy Employee Appreciation Day, ARK Team! ?? Today is all about YOU! We are incredibly grateful for your hard work, dedication, and the passion you bring every day. Your commitment to excellence and teamwork is what makes ARK special. We hope you take a moment to celebrate, have fun, and know just how much you’re appreciated. Thank you for everything you do—we couldn’t do it without you! ??
-
-
Did you know that Ark Clinical Research is dedicated to advancing clinical trials in pain management? #BetterResearchforaBetterLife
-
-
A huge shoutout to our?PBMC lab staff?at?Ark Clinical Research?for their dedication and hard work! We recently received feedback that?ARK had the top cell viability out of all the PBMC sites for a study, highlighting our team’s commitment to excellence. Your efforts make a difference, and we truly appreciate all that you do!????? #BetterResearchforaBetterLife
-
Join Us for Happy Hour with Dr. Justin Yanuck! Mark your calendar for?February 27th?and discover the latest breakthrough in pain management! Dr.?Justin Yanuck, a?double board-certified physician in Interventional Pain Management and Emergency Medicine, will be discussing the approval of a?new non-opioid pain relief medication?and its?impact on the future of healthcare. With specialized training from?Harvard’s Massachusetts General Hospital?and?UC Irvine, Dr. Yanuck brings cutting-edge expertise in innovative pain treatments. This is a unique opportunity to learn about the?next generation of pain relief?from a leading expert in the field. ???Don't miss this engaging discussion—join us for drinks, networking, and groundbreaking insights!
-
-
Congratulations to the ARK Team and Dr. Vutikullird on Reaching the First Randomization Milestone! ?? The Study Team is thrilled to celebrate this significant achievement! Reaching First Randomization is a testament to your dedication, teamwork, and commitment to advancing clinical research in patients with Cirrhosis! A huge thank you to the ARK team and Dr. Vutikullird for your hard work and contributions. We appreciate your efforts and look forward to many more milestones ahead! #BetterResearchforaBetterLife
-
Thank You for Joining Us at ARK Clinical Research’s Mobile Unit Event! We are incredibly grateful to everyone who attended and supported our Mobile Unit Event.?Your presence and engagement made this event a success! Together, we are bringing clinical research closer to the community, expanding access to healthcare, and making a meaningful impact. We appreciate your support and look forward to continuing this journey with you. Stay connected for more updates on how ARK Clinical Research is driving innovation in clinical trials! Subscribe to our calendar here: https://lnkd.in/gxSVRf7f #BetterResearchforaBetterLife
-
-
-
-
-
+1
-
-
Join us on?January 30, 2025, for ARK Clinical Research’s?Mobile Unit Event! Discover how we’re bringing clinical trials directly to the community and creating opportunities for improved healthcare access. We look forward to seeing you there! RSVP Here! https://lnkd.in/gUh66_cB
-